COST-EFFECTIVENESS OF BEVACIZUMAB AND RANIBIZUMAB AS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR PATIENTS WITH EYE DISORDERS: A SYSTEMATIC REVIEW. kjif [Internet]. 2024 Apr. 29 [cited 2026 Oct. 1];9(1):37-53. Available from: https://kjif.unjani.ac.id/kjif/article/view/658